VIEWRAY, INC. (NASDAQ:VRAY) Files An 8-K Other Events
On January30, 2017 ViewRay, Inc. (the Company) entered into an At
Market Sales Issuance Agreement (the Sales Agreement) with FBR
Capital Markets Co. (FBR) to sell shares of the Companys common
stock, par value $0.01 per share (the Common Stock), through an
at the market equity offering program under which FBR will act as
The shares will be issued to the Companys shelf registration
statement on Form S-3 (Registration No.333-215815). The Company
filed a prospectus supplement, dated April13, 2017, in connection
with the offer and sale of shares to the Sales Agreement.
|Item9.01||Financial Statements and Exhibits.|
|5.1||Opinion of Latham Watkins LLP.|
About VIEWRAY, INC. (NASDAQ:VRAY)
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed. VIEWRAY, INC. (NASDAQ:VRAY) Recent Trading Information
VIEWRAY, INC. (NASDAQ:VRAY) closed its last trading session down -0.10 at 6.90 with shares trading hands.